<title>Abstract</title> <italic>Candida albicans</italic> infections are a global health thread and challenge healthcare environments due to acquired resistances against prominent antifungals like amphotericin B and fluconazole, which additionally have severe adverse effects. The peptide Pom-1 originally isolated from the freshwater mollusk <italic>Pomacea poeyana</italic>, and its derivatives Pom-1A-F have proven their potential against biofilms of clinical <italic>C. albicans </italic>isolates and were suspected to act without candidolytic pore-formation. Here, Pom-1 and its derivatives were shown to act as neutralizing antimicrobial peptides (nAMPs) inhibiting cell-cell interactions and hence biofilm formation. Combining Pom-1 nAMPs with fluconazole and amphotericin B restored their efficacy against resistant <italic>C. albicans</italic>isolates. Addition of Pom-1 nAMPs allowed to reduce required concentrations to 10 – 50% below their described effective therapeutic doses. This opens doors not only to mitigate adverse effects of fluconazole and amphotericin B therapies, but also towards novel combination therapies against <italic>C. albicans</italic> as a severe re-emerging pathogen.